Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study

被引:7
作者
Xu, Junhui [1 ]
Wang, Mangju [1 ]
Shen, Ye [1 ]
Yan, Miao [1 ]
Xie, Weiwei [1 ]
Wang, Bingjie [1 ]
Liu, Huihui [1 ]
Cen, Xinan [1 ]
机构
[1] Peking Univ First Hosp, Dept Hematol, 8 Xi Shi Ku St, Beijing 100034, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2021年 / 13卷
关键词
symptomatic multiple myeloma; smoldering multiple myeloma; AL amyloidosis; poor prognostic factor; AL AMYLOIDOSIS; STAGING SYSTEM; DIAGNOSIS; CRITERIA;
D O I
10.2147/CMAR.S287922
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Amyloid light-chain amyloidosis (AL amyloidosis) is commonly associated with multiple myeloma. However, the clinical characteristics and prognosis of symptomatic and smoldering multiple myeloma with AL amyloidosis are not particularly clear. Methods: Patients with symptomatic and smoldering multiple myeloma in the Peking University First Hospital registry from 2010 to 2018 were studied. The clinical and laboratory information was collected from first presentation to death or until the last available clinical follow-up. The patients' survival and outcomes were analyzed, and the relationship between the clinical parameters and survival was also assessed. Results: Compared with symptomatic multiple myeloma patients without AL amyloidosis, patients with AL amyloidosis had higher incidence of BNP >= 700pg/mL (P<0.001), ALP>187.5IU/L (P=0.032) and ALB<25g/L (P<0.001). Similarly, compared with smoldering multiple myeloma patients without AL amyloidosis, patients with AL amyloidosis had higher incidence of BNP >= 700pg/mL (P=0.030) and Alb<25g/L (P=0.024). The existence of AL amyloidosis, especially those with the heart involvement, was related to shorter long-term survival of symptomatic and smoldering multiple myeloma according to univariate analyses. Renal involvement and gastrointestinal tract involvement had an impact on the prognosis of smoldering multiple myeloma but not on the symptomatic multiple myeloma. Cox regression model for overall survival detected BNP >= 700pg/mL in symptomatic multiple myeloma having independent poorer prognostic significance (HR=2.455, P=0.004). Interestingly, BNP at diagnosis was significantly correlated with cardiac amyloidosis (r=0.496, P<0.001). Cox regression model for overall survival detected the presence of AL amyloidosis in smoldering multiple myeloma having independent poorer prognostic significance (HR=8.741, P=0.002). Conclusion: AL amyloidosis is an independent poor prognostic factor for not only symptomatic multiple myeloma but also smoldering multiple myeloma. It is mainly because of involvement of important organs, especially the heart. AL amyloidosis probably has a greater impact on the prognosis of smoldering multiple myeloma than on the symptomatic multiple myeloma.
引用
收藏
页码:1343 / 1356
页数:14
相关论文
共 50 条
  • [31] A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee
    Fuchida, Shin-ichi
    Ogura, Mizuki
    Ishida, Tadao
    Hata, Hiroyuki
    Handa, Hiroshi
    Katoh, Nagaaki
    Nakaseko, Chiaki
    Sunami, Kazutaka
    Katayama, Yuta
    Nobata, Hironobu
    Oshiro, Kazuiku
    Iida, Shinsuke
    Sekijima, Yoshiki
    Naiki, Hironobu
    Shimazaki, Chihiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (04) : 443 - 449
  • [32] Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study
    Yoshitaka Kikukawa
    Hiromichi Yuki
    Sinya Hirata
    Kazuhiko Ide
    Hirotomo Nakata
    Toshikazu Miyakawa
    Naofumi Matsuno
    Kisato Nosaka
    Yuji Yonemura
    Tatsuya Kawaguchi
    Hiroyuki Hata
    Hiroaki Mitsuya
    Yutaka Okuno
    International Journal of Hematology, 2015, 101 : 133 - 139
  • [33] Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study
    Kikukawa, Yoshitaka
    Yuki, Hiromichi
    Hirata, Sinya
    Ide, Kazuhiko
    Nakata, Hirotomo
    Miyakawa, Toshikazu
    Matsuno, Naofumi
    Nosaka, Kisato
    Yonemura, Yuji
    Kawaguchi, Tatsuya
    Hata, Hiroyuki
    Mitsuya, Hiroaki
    Okuno, Yutaka
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (02) : 133 - 139
  • [34] Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data
    Quock, Tiffany P.
    Yan, Tingjian
    Chang, Eunice
    Guthrie, Spencer
    Broder, Michael S.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (06) : 549 - 559
  • [35] Epidemiology and clinical outcomes of light-chain amyloidosis in Sweden: A nationwide population-based study
    Mellqvist, Ulf-Henrik
    Cai, Qian
    Hester, Laura L.
    Grovdal, Michael
    Borsum, Jakob
    Rahman, Iffat
    Ammann, Eric M.
    Hansson, Markus
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (05) : 697 - 705
  • [36] Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study
    Ingebrigtsen, Andreas
    Saeed, Sahrai
    Larsen, Terje Hjalmar
    Reikvam, Hakon
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2024, 84 (03) : 193 - 201
  • [37] Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study
    Kunacheewa, Chutima
    Lee, Hans C.
    Patel, Krina
    Thomas, Sheeba
    Amini, Behrang
    Srour, Samer
    Bashir, Qaiser
    Nieto, Yago
    Qazilbash, Muzzaffar H.
    Weber, Donna M.
    Feng, Lei
    Orlowski, Robert Z.
    Lin, Pei
    Manasanch, Elisabet E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (05) : E221 - +
  • [38] Suggestive Diagnostic Process in a Case of Multiple Myeloma with Gastrointestinal Immunoglobulin Light-Chain Amyloidosis Accompanied by Protein-Losing Enteropathy
    Endo, Katsuya
    Ito, Takehito
    Nomura, Jun
    Murakami, Keigo
    Kondo, Shiho
    Satoh, Tomonori
    Fukushi, Daisuke
    Yoshino, Yuki
    Sasaki, Yoshiteru
    Takasu, Atsuko
    Kogure, Takayuki
    Hirota, Morihisa
    Meguro, Takayoshi
    Murakami, Kazuhiro
    Kameoka, Junichi
    Satoh, Kennichi
    CASE REPORTS IN GASTROINTESTINAL MEDICINE, 2021, 2021
  • [39] Prevalence, clinical characteristics and treatment outcome of factor X deficiency in a consecutive cohort of primary light-chain amyloidosis
    Gao, Ya-juan
    Shen, Kai-ni
    Chang, Long
    Feng, Jun
    Mao, Yue-ying
    Zhang, Lu
    Cao, Xin-xin
    Zhou, Dao-bin
    Li, Jian
    LEUKEMIA RESEARCH, 2022, 120
  • [40] The Clinicopathologic Features and the Factors Associated with the Survival in Light -Chain Amyloidosis Patients: A Single Center Descriptive Study
    Aytan, Pelin
    Yeral, Mahmut
    Gereklioglu, Cigdem
    Kasar, Mutlu
    Korur, Asli
    Buyukkurt, Nurhilal
    Asma, Suheyl
    Kozanoglu, Ilknur
    Ozdogu, Hakan
    Boga, Can
    MEDICAL JOURNAL OF BAKIRKOY, 2020, 16 (03) : 248 - 255